U.S. Markets closed

Prothena Corp PLC (PRTA) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Prothena Corp PLC (PRTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion. Prothena Corp PLC has a market cap of $572.040 million; its shares were traded at around $14.35 with and P/S ratio of 574.00.


For the last quarter Prothena Corp PLC reported a revenue of $0.19 million, compared with the revenue of $0.23 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $0.96 million, a decrease of 96.5% from the previous year. For the last five years Prothena Corp PLC had an average revenue decline of 1.5% a year.

The reported loss per diluted share was $3.93 for the year, compared with the loss per share of $0.29 in the previous year. The Prothena Corp PLC had an operating margin of -14943.46%, compared with the operating margin of -564.17% a year before. The 10-year historical median operating margin of Prothena Corp PLC is -3266.12%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Prothena Corp PLC has the cash and cash equivalents of $427.7 million, compared with $417.6 million in the previous year. The company had no long term debt, compared with $51.5 million in the previous year. Prothena Corp PLC has a financial strength rank of 5 (out of 10).

At the current stock price of $14.35, Prothena Corp PLC is traded at 79.8% premium to its historical median P/S valuation band of $7.98. The P/S ratio of the stock is 574.00, while the historical median P/S ratio is 319.37. The stock lost 59.69% during the past 12 months.

For the complete 20-year historical financial data of PRTA, click here.

This article first appeared on GuruFocus.